Vasalgel

Announcing the new Revolution Contraceptives website

The Parsemus Foundation began working on a new male contraceptive called Vasalgel a number of years ago. In 2013, Revolution Contraceptives was formed as a social venture company to develop Vasalgel and bring it to market. Revolution Contraceptives has grown over the last couple of years to meet the increasingly diverse and complex demands related… Read more


Vasalgel funding boosted by $200K grant from MCI

Revolution Contraceptives received a $200,000 grant from the Male Contraceptive Initiative (MCI) to advance Vasalgel towards human trials. The grant will support preclinical studies that will evaluate contraceptive effectiveness, procedural simplicity, reversibility, and safety. This proof-of-concept study will build on results from earlier preclinical studies and should support a future application for clinical trials in… Read more


Ed Gillis travels to advance Vasalgel

Ed Gillis, CEO of Revolution Contraceptives, the social venture company tasked with developing Vasalgel for Parsemus Foundation, traveled to Paris this spring to exchange ideas with other male contraceptive innovators at the second International Congress on Male Contraception. He aimed to network with others in the field, learn about other male contraceptives in development, and… Read more


Vasalgel highlighted in list of reproductive advances

Vasalgel made the Daily Beast’s list of the medical advances in 2017 that “are going to not only dramatically transform how we think about the birds and the bees but also the very way we think about reproduction.” In the December 25, 2017 article by senior science editor Tanya Basu, Vasalgel was heralded as the frontrunner… Read more


Study: new male contraceptives will reduce unintended pregnancies

How will the availability of new male contraceptive options impact the number of unintended pregnancies? Researchers recently created a model to answer that question in a paper published in Contraception. They focused the analysis on three countries (United States, South Africa and Nigeria) which differed by the type and rate of contraceptive use. By analyzing… Read more


Success! Publication of Vasalgel reversal study

Successful reversal of Vasalgel male contraceptive in rabbits For immediate release: Vasalgel’s prevention of sperm transport in the vas deferens for 14 months was reversed through an injection of sodium bicarbonate. Sperm concentration and motility returned to baseline. Results of a study of a promising new male contraceptive called VasalgelTM were published today in Basic… Read more